These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32124140)

  • 1. Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling.
    Jansson M; Billing O; Herdenberg C; Lundin C; Tolockiene E; Nazemroaya A; Sund M
    J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):69-77. PubMed ID: 32124140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
    Beltjens F; Molly D; Bertaut A; Richard C; Desmoulins I; Loustalot C; Charon-Barra C; Courcet E; Bergeron A; Ladoire S; Jankowski C; Boidot R; Arnould L
    Int J Cancer; 2021 Jul; 149(1):200-213. PubMed ID: 33634878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating microRNA-based screening tool for breast cancer.
    Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
    Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
    Yie SM; Luo B; Ye NY; Xie K; Ye SR
    Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
    He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
    Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy modifies serum pyrrolidone carboxypeptidase specific activity in women with breast cancer and influences circulating levels of GnRH and gonadotropins.
    Ramírez-Expósito MJ; Martínez-Martos JM; Dueñas-Rodríguez B; Navarro-Cecilia J; Carrera-González MP
    Breast Cancer Res Treat; 2020 Aug; 182(3):751-760. PubMed ID: 32506336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Relative Telomere Length is Associated With hTERT Gene Expression in the Tissue of Patients With Breast Cancer.
    Thriveni K; Raju A; Kumar RV; Krishnamurthy S; Chaluvarayaswamy R
    Clin Breast Cancer; 2019 Feb; 19(1):27-34. PubMed ID: 30217473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients.
    Silva J; García V; García JM; Peña C; Domínguez G; Díaz R; Lorenzo Y; Hurtado A; Sánchez A; Bonilla F
    Breast Cancer Res; 2007; 9(4):R55. PubMed ID: 17711569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients.
    Al-Ansari MM; Al-Saif M; Arafah M; Eldali AM; Tulbah A; Al-Tweigeri T; Semlali A; Khabar KS; Aboussekhra A
    Breast Cancer Res; 2020 May; 22(1):49. PubMed ID: 32414408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
    Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
    Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposite Prognostic Impact of Single PTEN-loss and
    Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
    Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
    Wolf B; Goebel G; Hackl H; Fiegl H
    BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Novel Breast Cancer Risk Loci.
    Chan CHT; Munusamy P; Loke SY; Koh GL; Wong ESY; Law HY; Yoon CS; Tan MH; Yap YS; Ang P; Lee ASG
    Cancer Res; 2017 Oct; 77(19):5428-5437. PubMed ID: 28775167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
    Karsten M; Stempel M; Radosa J; Patil S; King TA
    Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
    Mohammad AM; Abdel HA; Abdel W; Ahmed AM; Wael T; Eiman G
    Indian J Cancer; 2006; 43(4):163-8. PubMed ID: 17192687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
    Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
    Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression and protein deposition of major basement membrane components and TGF-beta 1 in human breast cancer.
    Nerlich AG; Wiest I; Wagner E; Sauer U; Schleicher ED
    Anticancer Res; 1997; 17(6D):4443-9. PubMed ID: 9494547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.